Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Translational Research and Cellular Therapeutics, Diabetes and Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, USA.
Biomed Pharmacother. 2021 Jan;133:110944. doi: 10.1016/j.biopha.2020.110944. Epub 2020 Nov 20.
Ischemia reperfusion injury (IRI) is a condition that occurs wherever blood flow and oxygen is reduced or absent, such as trauma, vascular disease, stroke, and solid organ transplantation. This condition can lead to tissue damage, especially during organ transplantation. Under such circumstances, some signaling pathways are activated, leading to up- or down- regulation of several genes such as microRNAs (miRNAs) that might attenuate or ameliorate this status. Therefore, by manipulating miRNAs level, they can be used as a biomarker for early diagnosis of IRI or suggestive to be therapeutic agents in clinical situation in future.
缺血再灌注损伤（IRI）是一种在血流和氧气减少或缺失时发生的情况，如创伤、血管疾病、中风和实体器官移植。这种情况会导致组织损伤，特别是在器官移植过程中。在这种情况下，一些信号通路被激活，导致几个基因（如 microRNAs，miRNAs）的上调或下调，这可能减轻或改善这种状态。因此，通过操纵 miRNA 的水平，可以将其用作 IRI 的早期诊断生物标志物，或在未来的临床情况下作为治疗剂。
